Westfield Capital Management Co. LP Sells 6,445 Shares of Cencora, Inc. $COR

Westfield Capital Management Co. LP reduced its stake in shares of Cencora, Inc. (NYSE:COR) by 2.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 319,215 shares of the company’s stock after selling 6,445 shares during the period. Westfield Capital Management Co. LP owned approximately 0.16% of Cencora worth $107,815,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in COR. Norges Bank bought a new stake in shares of Cencora during the 4th quarter worth $822,506,000. Marshall Wace LLP lifted its stake in Cencora by 518.9% in the third quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock worth $623,534,000 after purchasing an additional 1,672,762 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Cencora by 528.9% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock worth $461,250,000 after purchasing an additional 1,241,186 shares during the last quarter. Viking Global Investors LP lifted its stake in Cencora by 95.0% in the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after purchasing an additional 1,013,913 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Cencora by 4.1% in the third quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company’s stock worth $7,311,810,000 after purchasing an additional 916,506 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

Cencora Price Performance

COR stock opened at $270.12 on Friday. The firm’s 50-day moving average price is $293.70 and its two-hundred day moving average price is $330.94. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54. The stock has a market capitalization of $52.55 billion, a price-to-earnings ratio of 20.71, a PEG ratio of 1.42 and a beta of 0.59. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. During the same quarter in the previous year, the firm posted $4.42 EPS. Cencora’s revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities analysts predict that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora declared that its Board of Directors has initiated a stock repurchase plan on Thursday, May 21st that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 3.9% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were given a dividend of $0.60 per share. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. Cencora’s payout ratio is currently 18.40%.

Analysts Set New Price Targets

Several analysts have weighed in on COR shares. William Blair started coverage on shares of Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating for the company. Barclays boosted their price target on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research note on Friday, February 13th. Morgan Stanley set a $342.00 price target on shares of Cencora in a research note on Friday, May 8th. Citigroup lowered their price target on shares of Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, Robert W. Baird lowered their price target on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Twelve equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $380.25.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.